BUZZ-Myriad Genetics falls after preliminary Q4 revenue misses estimates

** Shares of medical test kit maker Myriad Genetics MYGN.O fall ~3% to $13.27

** MYGN says it expects Q4 rev. to be between $209 mln and $211 mln, below analyst estimates of $212.9 mln - data compiled by LSEG

** Co expects Q4 adj. EPS to be between 3 cents and 4 cents vs. analyst est. of 3 cents

** Co forecasts 2025 rev. to be between $840 mln and $860 mln below analyst est. of $876.7 mln

** Co forecasts 2025 adj. EPS to be between 7 cents and 11 cents vs. analyst est. of 8 cents

** 6 of 16 brokerages rate the stock "buy" or higher, 6 "hold" and 4 "sell" or lower; their median PT is $20.50 - LSEG

** MYGN fell 27.5% in 2024

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))